MX2015016382A - Vacunas contra el virus de la influenza y sus usos. - Google Patents

Vacunas contra el virus de la influenza y sus usos.

Info

Publication number
MX2015016382A
MX2015016382A MX2015016382A MX2015016382A MX2015016382A MX 2015016382 A MX2015016382 A MX 2015016382A MX 2015016382 A MX2015016382 A MX 2015016382A MX 2015016382 A MX2015016382 A MX 2015016382A MX 2015016382 A MX2015016382 A MX 2015016382A
Authority
MX
Mexico
Prior art keywords
domain
amino acids
terminal
influenza virus
influenza hemagglutinin
Prior art date
Application number
MX2015016382A
Other languages
English (en)
Other versions
MX369317B (es
Inventor
Anthony Williamson Robert
Wadia Jehangir
Radosevic Katarina
IMPAGLIAZZO Antonieta
Wilem Meijberg Jan
Wagner Michelle
Ding Zhaoqing
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of MX2015016382A publication Critical patent/MX2015016382A/es
Publication of MX369317B publication Critical patent/MX369317B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona polipéptidos con dominio de tallo de hemaglutinina de influenza que comprenden (a) un dominio HA1 de hemaglutinina de influenza que comprende un segmento de tallo N-terminal de HA1, que comprende los aminoácidos de la posición 1 a la posición x, preferentemente de la posición p a la posición x, del dominio HA1, unido covalentemente mediante una secuencia de enlace de 0-50 residuos de aminoácido a un segmento de tallo C-terminal de HA1, que comprende los aminoácidos de la posición y hasta e incluyendo el aminoácido C-terminal del dominio HA1 y (b) un dominio HA2 de hemaglutinina de influenza, donde el polipéptido con dominio de tallo de hemaglutinina es resistente a la escisión de proteasas en el empalme entre HA1 y HA2, y donde uno o más aminoácidos de los aminoácidos en las posiciones 337, 340, 352, 353, 402, 406, 409, 413 y/o 416 han sido mutados en comparación con las posiciones correspondientes en la HA de influenza de tipo natural.
MX2015016382A 2013-05-30 2014-05-27 Vacunas contra el virus de la influenza y sus usos. MX369317B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13169830 2013-05-30
PCT/EP2014/060997 WO2014191435A1 (en) 2013-05-30 2014-05-27 Influenza virus vaccines and uses thereof

Publications (2)

Publication Number Publication Date
MX2015016382A true MX2015016382A (es) 2016-10-14
MX369317B MX369317B (es) 2019-11-05

Family

ID=48485075

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016382A MX369317B (es) 2013-05-30 2014-05-27 Vacunas contra el virus de la influenza y sus usos.

Country Status (17)

Country Link
US (1) US10517941B2 (es)
EP (1) EP3004142B1 (es)
JP (1) JP6643981B2 (es)
KR (1) KR102252163B1 (es)
CN (1) CN105452270B (es)
AU (1) AU2014273173B2 (es)
BR (1) BR112015029635B1 (es)
CA (1) CA2913859C (es)
EA (1) EA034639B1 (es)
HK (1) HK1223110A1 (es)
IL (1) IL242824B (es)
MX (1) MX369317B (es)
MY (1) MY190097A (es)
PH (1) PH12015502612B1 (es)
SG (1) SG11201509663PA (es)
WO (1) WO2014191435A1 (es)
ZA (1) ZA201509229B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3566714A1 (en) 2011-11-28 2019-11-13 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
EA034639B1 (ru) 2013-05-30 2020-03-02 Янссен Вэксинс Энд Превеншн Б.В. Вакцины против вируса гриппа и их применения
WO2015187158A1 (en) * 2014-06-04 2015-12-10 Indevr, Inc. Universal capture array for multiplexed subtype-specific quantification and stability determination of influenza proteins
AU2015279089B2 (en) 2014-06-26 2021-01-28 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
PE20170290A1 (es) * 2014-07-10 2017-03-26 Janssen Vaccines And Prevention B V Vacunas contra virus de influenza y usos de las mismas
EA035375B1 (ru) 2014-07-10 2020-06-03 Янссен Вэксинс Энд Превеншн Б.В. Вакцины против вируса гриппа и их применения
KR20240042570A (ko) * 2016-09-02 2024-04-02 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
WO2018210804A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
JP7406377B2 (ja) 2017-05-15 2023-12-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定なウイルス含有組成物
EP3664839A4 (en) * 2017-10-04 2021-10-20 Georgia State University Research Foundation, Inc. HEADLESS HEMAGGLUTININ INFLUENZA Vaccine
HUE059545T2 (hu) 2018-01-23 2022-11-28 Janssen Vaccines & Prevention Bv Influenzavírus-vakcinák és alkalmazásaik
KR20220057578A (ko) 2019-09-05 2022-05-09 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도
WO2023154841A2 (en) * 2022-02-11 2023-08-17 The Texas A&M University System Sars-cov-2 neutralizing synthetic proteins
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
MY170607A (en) 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2010117786A1 (en) * 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
MY183517A (en) 2009-05-11 2021-02-24 Janssen Vaccines & Prevention Bv Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
JP2013526849A (ja) 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
CN103906763B (zh) 2011-07-14 2016-10-12 克鲁塞尔荷兰公司 能够中和系统发育群1和系统发育群2的a型流感病毒以及b型流感病毒的人结合分子
EP3566714A1 (en) * 2011-11-28 2019-11-13 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
EA034639B1 (ru) 2013-05-30 2020-03-02 Янссен Вэксинс Энд Превеншн Б.В. Вакцины против вируса гриппа и их применения
PE20170290A1 (es) 2014-07-10 2017-03-26 Janssen Vaccines And Prevention B V Vacunas contra virus de influenza y usos de las mismas
EA035375B1 (ru) 2014-07-10 2020-06-03 Янссен Вэксинс Энд Превеншн Б.В. Вакцины против вируса гриппа и их применения

Also Published As

Publication number Publication date
PH12015502612A1 (en) 2016-02-29
US10517941B2 (en) 2019-12-31
EP3004142A1 (en) 2016-04-13
NZ715583A (en) 2021-02-26
ZA201509229B (en) 2022-03-30
HK1223110A1 (zh) 2017-07-21
CA2913859A1 (en) 2014-12-04
PH12015502612B1 (en) 2016-02-29
EA201592306A1 (ru) 2016-05-31
CA2913859C (en) 2021-11-30
KR20160013205A (ko) 2016-02-03
IL242824B (en) 2020-07-30
EA034639B1 (ru) 2020-03-02
US20160136262A1 (en) 2016-05-19
CN105452270B (zh) 2020-12-01
KR102252163B1 (ko) 2021-05-14
JP2016525889A (ja) 2016-09-01
SG11201509663PA (en) 2015-12-30
BR112015029635B1 (pt) 2023-05-02
MY190097A (en) 2022-03-28
JP6643981B2 (ja) 2020-02-12
WO2014191435A1 (en) 2014-12-04
BR112015029635A2 (pt) 2017-09-26
EP3004142B1 (en) 2020-09-30
CN105452270A (zh) 2016-03-30
AU2014273173A1 (en) 2015-12-10
AU2014273173B2 (en) 2018-09-27
MX369317B (es) 2019-11-05

Similar Documents

Publication Publication Date Title
PH12015502612B1 (en) Influenza virus vaccines and uses thereof
PH12014501118A1 (en) Influenza virus vaccines and uses thereof
MX2017006866A (es) Pares de unión para producción de péptidos.
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
MX343386B (es) Proteinas de fusion portadoras de peptido como vacunas para alergia.
CO2017004318A2 (es) Variantes de interferon α2b
CY1120578T1 (el) Μιγμα πεπτιδιων
PE20170290A1 (es) Vacunas contra virus de influenza y usos de las mismas
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
ES2531288T3 (es) Proteína de fusión anticancerígena
MX2018015755A (es) Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
MX340735B (es) Proteinas multimericas recombinantes de la influenza.
MX2016011394A (es) Moleculas de andamiaje a base de fibronectina estabilizada.
MX2021012991A (es) Antigenos de gripe recombinantes.
MX2017015927A (es) Fragmentos mutantes de proteina ras.
HRP20220980T1 (hr) Cjepiva protiv virusa influence i njihova uporaba
MX2016014633A (es) Nuevos derivados de cath2.
EA201591609A1 (ru) Варианты альфа-амилазы
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
CY1123664T1 (el) Εμβολιο
MX2015011931A (es) Expresion mejorada de proteinas de picornavirus.
SG10201908920QA (en) Influenza virus vaccines and uses thereof
EA201590431A1 (ru) Пшеница с новыми аллелями rht-b1
NZ706202A (en) Peptide antagonists of the vasopressin-2 receptor
MX2018009692A (es) Inductor de inmunidad.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: CENTREXION THERAPEUTICS CORPORATION

FG Grant or registration